Share-based Payment Arrangement, Expense of Enlivex Therapeutics Ltd. from 31 Dec 2020 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Enlivex Therapeutics Ltd. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2020 to 30 Jun 2025.
  • Enlivex Therapeutics Ltd. Share-based Payment Arrangement, Expense for the quarter ending 30 Jun 2025 was $295,000, a 24% decline year-over-year.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2024 was $2,065,000, a 5.8% increase from 2023.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2023 was $1,951,000, a 28% decline from 2022.
  • Enlivex Therapeutics Ltd. annual Share-based Payment Arrangement, Expense for 2022 was $2,712,000, a 6.9% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Enlivex Therapeutics Ltd. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $295,000 -$93,000 -24% 01 Apr 2025 30 Jun 2025 6-K 29 Aug 2025 2025 Q2
Q2 2024 $388,000 -$123,000 -24% 01 Apr 2024 30 Jun 2024 6-K 29 Aug 2025 2025 Q2
Q2 2023 $511,000 01 Apr 2023 30 Jun 2023 6-K 30 Aug 2024 2024 Q2

Enlivex Therapeutics Ltd. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,065,000 +$114,000 +5.8% 01 Jan 2024 31 Dec 2024 20-F 30 Apr 2025 2024 FY
2023 $1,951,000 -$761,000 -28% 01 Jan 2023 31 Dec 2023 20-F 30 Apr 2025 2024 FY
2022 $2,712,000 -$202,000 -6.9% 01 Jan 2022 31 Dec 2022 20-F 30 Apr 2025 2024 FY
2021 $2,914,000 +$1,567,000 +116% 01 Jan 2021 31 Dec 2021 20-F 30 Apr 2024 2023 FY
2020 $1,347,000 01 Jan 2020 31 Dec 2020 20-F 29 Apr 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.